Core Viewpoint - Star Bulk Carriers Corp. reported a significant decline in financial performance for Q1 2025 compared to Q1 2024, with a net income of $0.5 million and a decrease in voyage revenues, while announcing a new minimum quarterly dividend policy of $0.05 per share [1][4][8]. Financial Performance - Voyage revenues decreased to $230.7 million in Q1 2025 from $259.4 million in Q1 2024 [20]. - Net income fell sharply to $0.5 million in Q1 2025 from $74.9 million in Q1 2024 [18]. - Adjusted net loss for Q1 2025 was $7.7 million, compared to an adjusted net income of $73.2 million in Q1 2024 [18][46]. - EBITDA decreased to $58.0 million in Q1 2025 from $126.3 million in Q1 2024 [19][42]. - Adjusted EBITDA was $49.0 million in Q1 2025, down from $123.0 million in Q1 2024 [19][42]. Operational Metrics - The average number of vessels increased to 150.7 in Q1 2025 from 113.3 in Q1 2024 [34]. - Daily Time Charter Equivalent (TCE) rate dropped to $12,439 per day in Q1 2025 from $19,627 per day in Q1 2024, reflecting weaker market conditions [20][35]. - Daily operating expenses per vessel (as adjusted) were $4,898 in Q1 2025, slightly down from $4,962 in Q1 2024 [22][35]. Dividend and Share Repurchase - The Board declared a quarterly cash dividend of $0.05 per share, marking the 17th consecutive quarter of capital returns [5][8]. - Approximately 1.3 million shares were repurchased at an average price of $15.24 per share during Q1 2025, totaling $19.6 million [9]. Fleet and Asset Management - The company agreed to sell five Supramax vessels as part of its strategy to dispose of older and smaller tonnage [6]. - Following recent vessel sales, the company will have 13 unencumbered vessels and expects to collect total net proceeds of approximately $44.4 million in Q2 2025 [14]. Financial Position - The company reported over $500 million in liquidity and net debt below scrap value [7]. - As of March 31, 2025, total assets were $4.02 billion, with total liabilities of $1.56 billion [32].

Core Viewpoint - CytoSorbents Corporation reported its financial results for Q1 2025, highlighting strong revenue growth in the EU despite temporary disruptions in Germany, and ongoing efforts to advance its product pipeline, particularly DrugSorb™-ATR, which aims to address life-threatening bleeding in cardiac surgery patients [1][4][5]. Financial Results - Product revenue for Q1 2025 was $8.7 million, a decrease of 3% from $9.0 million in Q1 2024, remaining flat on a constant currency basis [8]. - Gross margin decreased to 71% from 77% in Q1 2024 [8]. - Operating loss improved by 17% to $3.9 million compared to $4.7 million in Q1 2024, reflecting a 12% reduction in operating expenses [8]. - Net loss was $1.5 million or $0.02 per share, compared to a net loss of $6.1 million or $0.11 per share in Q1 2024 [8]. - Adjusted net loss was $3.7 million or $0.06 per share, compared to an adjusted net loss of $3.7 million or $0.07 per share in Q1 2024 [8]. - Adjusted EBITDA loss improved by 17% to $2.7 million compared to a loss of $3.3 million in Q1 2024 [8]. - Total cash, cash equivalents, and restricted cash increased to $13.1 million at March 31, 2025, from $9.8 million as of December 31, 2024 [8]. Business Highlights - The company is focused on bringing DrugSorb™-ATR to the North American market, addressing the unmet need for reducing life-threatening bleeding in patients on Brilinta® during CABG surgery [5][6]. - The FDA issued a denial letter regarding the De Novo Request for DrugSorb-ATR, but the company plans to resolve the outstanding items through a formal appeal process, expecting a final regulatory decision in 2025 [6][7]. - Real-world adoption of DrugSorb-ATR is increasing, with more heart centers incorporating the technology into standard care based on evidence from the international STAR Registry [7]. - The company completed a shareholder rights offering, raising $6.8 million, which increased liquidity and allowed for the release of $5.0 million of restricted cash [9]. Operational Developments - CytoSorbents opened a new regional sales subsidiary in Dubai, UAE, expanding its global footprint into the Middle East and Africa [9]. - The company appointed Thomas Shannon as Vice President of Marketing for North America to lead the marketing strategy for DrugSorb™-ATR [9].

American Society of Clinical Oncology (ASCO) GI Symposium data underscores pelareorep's clinical benefit in anal and pancreatic cancersPelareorep featured in Key Opinion Leader event on oncolytic immunotherapies in breast and pancreatic cancersPoster on pelareorep's stimulation of adaptive and innate immunity to be shared at ASCO Annual MeetingConference call and webcast today at 4:30 p.m. ET to discuss Q1 results and clinical outlookSAN DIEGO, Calif. and CALGARY, AB, May 14, 2025 /PRNewswire/ -- Oncolytics ...

Non-GAAP Net Income $5.24 million; Non-GAAP EPS $1.5; Record Gross Margin 63.3%TEL AVIV, Israel, May 14, 2025 /PRNewswire/ -- SuperCom (NASDAQ: SPCB), a global provider of secured solutions for the e-Government, IoT, and Cybersecurity sectors, today reported results for the first quarter, ended March 31, 2025.First Quarter Ended March 31, 2025, Financial Highlights (Compared to the First Quarter of 2024) Revenue increased to $7.05 million, from $6.85 million. Gross profit grew 18% to $4.5 million, from $3.8 ...

Company Overview - Vivos Therapeutics, Inc. is a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for sleep-related breathing disorders, particularly obstructive sleep apnea (OSA) and snoring in adults, as well as moderate to severe OSA in children aged 6 to 17 [4] - The company's devices have received FDA clearance for treating all severity levels of OSA in adults and moderate to severe OSA in children [4] - Vivos' CARE devices are the only FDA 510(k) cleared technology for treating severe OSA in adults and the first to receive clearance for treating moderate to severe OSA in children [4] Industry Context - OSA affects over 1 billion people globally, with 90% remaining undiagnosed [5] - The disorder is linked to various serious chronic health conditions, indicating a significant unmet need in the market for effective treatment solutions [5] - Current solutions often fail to address the root causes of OSA, highlighting the importance of innovative approaches like those offered by Vivos [5] Upcoming Events - Vivos plans to release its first quarter 2025 financial results after market close on May 15, 2025, followed by a conference call at 5:00 p.m. ET to discuss the results and recent developments [1] - The conference call can be accessed via a dedicated phone line and will also be available as a live webcast on the company's website [2][3] Innovative Approach - The Vivos Method provides a proprietary, clinically effective solution that is nonsurgical, noninvasive, and nonpharmaceutical, aiming to improve patient outcomes in sleep health [7] - The company collaborates with healthcare providers, including dentists and sleep specialists, to address the complex needs of patients suffering from sleep-related disorders [6]

Core Insights - Blum Holdings, Inc. reported a revenue growth of 26% year-over-year, reaching $2.2 million in Q1 2025, compared to $1.8 million in Q1 2024, driven by strategic divestitures and new retail store additions [1][4] - The company achieved positive EBITDA of $57,000, a significant turnaround from an EBITDA loss of $3.0 million in Q1 2024, indicating improved operational efficiency [1][4] - Net loss from continuing operations was reduced by over 80%, down to $0.6 million from $3.5 million in Q1 2024, reflecting effective cost management and operational improvements [1][4] Financial Performance - Revenue increased to $2.2 million in Q1 2025 from $1.8 million in Q1 2024, marking a 26% increase [4][11] - Gross margin improved to 53%, up from 45% in both Q1 and Q4 2024, attributed to better pricing discipline and product mix [4][11] - Operating expenses decreased to $2.5 million from $4.4 million in Q1 2024, showcasing effective cost containment measures [4][11] - Adjusted EBITDA loss narrowed to $0.4 million, an 87% improvement year-over-year and 80% quarter-over-quarter [4][11] Strategic Developments - The company raised $1.6 million in capital in 2025 at competitive rates, enhancing its financial position [4] - Approval was received from the Bankruptcy Court for a settlement with People's, effective after a 14-day appeal period [4] - Brad Hirsch was appointed to the Board of Directors, enhancing governance and oversight [4] - An amended Letter of Intent (LOI) with a Bay Area dispensary is expected to generate approximately $12 million in annual revenue [4] Management Commentary - The CEO emphasized that the company has achieved breakeven operations on an EBITDA basis and is now strategically positioned for growth [5] - The focus remains on securing capital to strengthen the balance sheet and evaluating strategic acquisition opportunities to drive growth in the California cannabis market [5]

Core Viewpoint - Lucid Diagnostics Inc. has secured capital to extend its operational runway significantly, positioning the company to capitalize on upcoming reimbursement milestones and accelerate commercialization efforts for its EsoGuard product [4][6]. Business Highlights - The company is expanding cash-pay and contracted programs targeting concierge medicine practices and self-insured employers, while also gaining traction with regional commercial insurers for EsoGuard coverage [4]. - A partnership with a major health system has been established to launch a comprehensive EsoGuard esophageal precancer testing program, enhancing access for at-risk patients [6]. - The company has launched the "Embrace the Future" campaign to promote its EsoCheck® Cell Collection Device, which features innovative technology compared to traditional methods [6]. - A National Cancer Institute-sponsored study has shown that EsoGuard effectively detects esophageal precancer in at-risk patients without GERD, potentially increasing market opportunity by up to 70% [6]. Financial Results - For the three months ended March 31, 2025, Lucid processed 3,034 EsoGuard tests and recognized $0.8 million in revenue from EsoGuard [6]. - The company reported operating expenses of approximately $13.3 million, including $1.0 million in stock-based compensation, leading to a GAAP net loss of approximately $36.0 million or $(0.52) per share [6][9]. - The non-GAAP adjusted loss for the same period was approximately $11.2 million or $(0.16) per share [7][11]. - As of March 31, 2025, Lucid had cash and cash equivalents of $25.2 million, an increase from $22.4 million as of December 31, 2024, and completed a public offering for net proceeds of $16.1 million [10].

Core Insights - Advanced Flower Capital Inc. reported a GAAP net income of $4.1 million, translating to $0.18 per basic weighted average common share for Q1 2025 [1][2] - The company also reported Distributable Earnings of $4.5 million, or $0.21 per basic weighted average common share for the same period [1][2] Financial Performance - The net income for the first quarter of 2025 was $4,067,685, a significant improvement compared to a net loss of $54,116 in Q1 2024 [15] - Distributable Earnings for Q1 2025 were $4,543,906, down from $9,965,706 in Q1 2024, with Distributable Earnings per basic weighted average share decreasing from $0.49 to $0.21 [15][16] Dividend Information - The company paid a regular cash dividend of $0.23 per common share on April 15, 2025, for shareholders of record as of March 31, 2025 [3] Strategic Focus - The CEO emphasized the company's priority in reducing exposure to underperforming credits while maintaining discipline in providing debt capital to successful operators [3] - The company aims to leverage market dislocations to invest in quality credits with strong risk-adjusted returns [3] Company Overview - Advanced Flower Capital Inc. is a commercial mortgage REIT that provides loans to state law compliant cannabis operators in the U.S., with loans typically ranging from $10 million to over $100 million [8]

Core Insights - Nexxen International Ltd. reported record financial results for Q1 2025, driven by a 40% year-over-year growth in Connected TV (CTV) revenue and a 95% increase in Adjusted EBITDA [1][3][5] - The company completed a $50 million Ordinary Share repurchase program and initiated a new $50 million repurchase program in April 2025 [1][11] - Nexxen will host an investor day on May 22, 2025, to discuss its growth strategies and innovations [1][3] Financial Performance - Q1 2025 Contribution ex-TAC reached $75.0 million, an 8% increase year-over-year [5][10] - Programmatic revenue for Q1 2025 was $71.8 million, up 10% year-over-year, and accounted for 92% of total revenue compared to 88% in Q1 2024 [5][10] - Adjusted EBITDA for Q1 2025 was $23.1 million, reflecting a 95% increase year-over-year, with an Adjusted EBITDA margin of 31% on a Contribution ex-TAC basis [5][10][12] Operational Highlights - The company added 101 new actively spending first-time advertiser customers in Q1 2025 across various sectors, including travel and financial services [11] - Nexxen expanded its partnerships with major players in the industry, enhancing its advanced TV offerings and programmatic advertising capabilities [11] - The launch of nexAI, an AI-powered suite of tools, is expected to improve data usability and performance for clients [3][11] Financial Guidance - Nexxen reaffirmed its full-year 2025 financial guidance, projecting Contribution ex-TAC of approximately $380 million and Adjusted EBITDA of around $125 million [6][7] - The company remains confident in its guidance despite potential market softness due to economic uncertainties [6][7]

Core Insights - SFL Corporation Ltd. reported preliminary financial results for Q1 2025, including a net loss of $31.9 million or $0.24 per share, primarily due to impairments on older dry-bulk vessels and the idleness of the drilling rig Hercules [1][6] - The company declared a quarterly cash dividend of $0.27 per share, marking the 85th consecutive quarterly dividend [5][6] - Charter hire revenue for the quarter was $193.5 million, which included $1.5 million from profit share, while adjusted EBITDA was $108.0 million from consolidated subsidiaries and $7.7 million from associated companies [6] Financial Performance - The net loss of $31.9 million was attributed to one-off items, including impairments on older vessels [3][6] - Charter hire revenue was reported at $193.5 million, with an adjusted EBITDA of $115.7 million when including associated companies [6] - The company has been actively repurchasing shares, with a $10 million buyback at an average price of $7.98 per share [6] Fleet Management - SFL continues to renew its fleet by divesting older bulkers and containerships, focusing on assets with a charter backlog to support long-term dividend distribution [4][6] - The company upgraded several vessels during the quarter, enhancing cargo intake and fuel efficiency [3][4] Dividend Information - The declared quarterly cash dividend of $0.27 per share will be paid on or around June 27, 2025, with the record date set for June 12, 2025 [5][6] - This dividend reflects the company's commitment to maintaining a consistent distribution to shareholders [8]